Navigation Links
Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
Date:6/15/2012

AMSTERDAM, June 15, 2012 /PRNewswire/ --

At the 17th Congress of the European Hematology Association in Amsterdam Professor Max Topp of the University of Wuerzberg in Germany presents the impressive results with a bispecific antibody for Acute Lymphoblastic Leukemia patients.

The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant. Patients received blinatumomab for 28 days followed by two weeks off therapy over a six week treatment cycle, for up to five treatment cycles. Patients received a continuous intravenous infusion of blinatumomab at an initial dose of five or 15 micrograms/m2 per day, escalating to 30 micrograms for the remainder of the treatment. The primary endpoint of the study was the rate of complete remission (CR) and complete remission with partial hematologic recovery (CRh*). Secondary endpoints included molecular response rate, duration of response and overall survival. All 36 patients were evaluable for efficacy and safety.

Twenty-six of the 36 patients (72%) treated with blinatumomab across all of the tested doses and schedules achieved a CR/CRh*. All but two patients achieved a molecular response, meaning there was no evidence of leukemic cells by polymerase chain reaction. The most common adverse events were pyrexia, headache and tremor. Medically important safety events were reversible cytokine release syndrome and CNS adverse events.

At the time of the analysis, median survival was 9.0 (8.2, 15.8) months with a median follow-up period of 10.7 months. The median duration of response in the 26 patients who responded to treatment was 8.9 months.

About the EHA Annual Congress

After 16 congresses and constantly increasing number of delegates, the 17th'/>"/>

SOURCE European Hematology Association
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
2. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
3. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
4. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
5. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
6. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
7. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
8. MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
9. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012
10. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
11. GeneLink Reports First Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 ... today announces Michelle Detwiler as the new Director of ... current and potential clients as well as iLab sub-teams ... main goal will be to ensure that iLab provides ... offering the most advanced, user-friendly, and high-impact solution in ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014 ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... the United States Patent and Trademark Office ... for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, ... management ( SCM ) and sales and operations planning ... gold sponsor of the Biomanufacturing Summit , which ... January 30 – 31, 2014.  At the conference, join ... Chain at Amgen, as she presents ,Supply Chain: Improving ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental products, ... dual arch impressions on its dental blog. , ... entry serves up a list of tips to help dentists ... Dr. David Little as he crafts a porcelain crown using ... as the dual arch dental impression material . ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Pressure BioSciences, Inc. (Nasdaq: PBIO ) ... announced that they have entered into a strategic marketing, ... the Agreement, the companies will: (1) share market data, ... certain products at industry trade shows beginning in 2009; ...
... http://www.wellcentive.com ),today announced the launch of two new ... securely and cost-effectively share patient,data within a community ... such as physicians, to easily access patient data ... Connect is a health care technology platform,which receives ...
... NEW YORK, Dec. 11 Delcath Systems, Inc. (Nasdaq: ... its proprietary Percutaneous Hepatic Perfusion ("PHP") System for the treatment ... fifty percent (46 of 92) of patients have been enrolled ... ocular melanoma to the liver. The eleven participating cancer ...
Cached Biology Technology:Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 3Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 4Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 5WellCentive Launches New Health Information Exchange Platforms 2WellCentive Launches New Health Information Exchange Platforms 3Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3
(Date:4/16/2014)... to blame for significant baseline levels of arsenic in ... in the Journal of Environmental Quality . , ... of Ohio showed that every single sample had concentrations ... the U.S. Environmental Protection Agency. The findings should not ... regulatory levels typically are set far below those thought ...
(Date:4/15/2014)... and energy for nearly all life on Earth, yet ... example, little is known about how it is regulated ... we do not know the full list of the ... any organism. , , A type of single-cell green ... subject for photosynthesis research. Despite its importance in the ...
(Date:4/15/2014)... Worcester, Mass. Diana Lados, associate professor ... (WPI) and founding director of the university,s ... two major career achievement awards from leading ... in Detroit, SAE International, a global association ... technical experts in the automotive, aerospace, and ...
Breaking Biology News(10 mins):Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 2WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 3WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 4WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 5
... Jerusalem, November 21, 2010 Research work carried out ... warning in the growing field of the development of ... patients through replacement of diseased or damaged tissues by ... a possible danger of cancerous tissue development in the ...
... Consortium (IVCC) has received $50 million from the Bill ... develop new insecticides for the improved control of mosquitoes ... neglected tropical diseases. IVCC was established ... over five years from the foundation. Since then, ...
... prompts normal cells to transform themselves into cancerous cells? Researchers ... Antonio, have identified factors in the very first step of ... tube. The latter accomplishment was reported Sunday [Nov. 21] in ... The DNA molecule the elegant, twin-stranded necklace of ...
Cached Biology News:Hebrew University research carries cautionary warning for future stem cell applications 2Hebrew University research carries cautionary warning for future stem cell applications 3
COMING SOON: Anti-Mouse C5/C5b, Clone BB5.1. Monoclonal Antibody...
... Goat anti-Human Alpha 1 Acid ... azide Goats were immunized ... glycoprotein in Freund's adjuvant. ... absorbed to ensure specificity. ...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Request Info...
Biology Products: